第 1 到 71 筆結果,共 71 筆。
公開日期 | 標題 | 作者 | 來源出版物 | scopus | WOS | 全文 | |
---|---|---|---|---|---|---|---|
1 | 2010 | Unusual presentation of multiple pathologic bone fractures in a patient with gastric mucosa-associated lymphoid tissue lymphoma | SUNG-HSIN KUO ; RUOH-FANG YEN ; CHUNG-WU LIN ; Chen L.-T.; HWEI-FANG TIEN ; ANN-LII CHENG | Annals of Hematology | 1 | 1 | |
2 | 2016 | Tumor heterogeneity in hepatocellular carcinoma: Facing the challenges | LI-CHUN LU ; CHIH-HUNG HSU ; CHIUN HSU ; ANN-LII CHENG | Liver Cancer | 95 | 98 | |
3 | 2012 | Targeting fibroblast growth factor receptor signaling in hepatocellular carcinoma | ANN-LII CHENG ; Ying-Chun Shen ; Zhu A.X. | Oncology | 39 | 41 | |
4 | 2014 | Strategy for Preventing Hepatitis B Reactivation in Patients With Resolved Hepatitis B Virus Infection After Rituximab-Containing Chemotherapy Reply | CHIUN HSU ; PEI-JER CHEN ; ANN-LII CHENG | Hepatology | 0 | 0 | |
5 | 2009 | Strategies to prevent hepatitis B virus reactivation in patients receiving immunosuppressive therapy | CHIUN HSU ; SHU-CHEN WEI ; ANN-LII CHENG ; PEI-JER CHEN | Hepatology | 4 | 3 | |
6 | 1996 | Steroid-free chemotherapy decreases the risk of hepatitis flare-up in hepatitis B virus carriers with non-Hodgkin's lymphoma [3] | ANN-LII CHENG | Blood | 71 | 59 | |
7 | 2015 | Statin Use Is Associated With Improved Prognosis of Colorectal Cancer in Taiwan | YU-YUN SHAO ; CHIH-HUNG HSU ; KUN-HUEI YEH ; Chen H.-M.; Yeh Y.-C.; Lai C.-L.; ZHONG-ZHE LIN ; ANN-LII CHENG ; Lai M.-S. | Clinical Colorectal Cancer | 35 | 32 | |
8 | 2021 | Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of hepatocellular carcinoma | Greten T.F.; Abou-Alfa G.K.; ANN-LII CHENG ; Duffy A.G.; El-Khoueiry A.B.; Finn R.S.; Galle P.R.; Goyal L.; He A.R.; Kaseb A.O.; Kelley R.K.; Lencioni R.; Lujambio A.; Mabry Hrones D.; Pinato D.J.; Sangro B.; Troisi R.I.; Wilson Woods A.; Yau T.; Zhu A.X.; Melero I. | Journal for ImmunoTherapy of Cancer | 39 | 34 | |
9 | 1995 | Single-step direct cloning of PCR products | Chuang S.-E.; Wang K.-C.; ANN-LII CHENG | Trends in Genetics | 4 | 2 | |
10 | 1998 | Research nurses for clinical trials of anti-cancer drugs: Developing a new subspecialty in Taiwan | ANN-LII CHENG ; YEUR-HUR LAI ; Yu Y.-C. | Drug Information Journal | 0 | 0 | |
11 | 2018 | Reply to: “Predictors of sorafenib benefit in patients with hepatocellular carcinoma” | Bruix J.; ANN-LII CHENG ; Llovet J. | Journal of Hepatology | 1 | 0 | |
12 | 2018 | Recent developments of c-Met as a therapeutic target in hepatocellular carcinoma | Bouattour M.; Raymond E.; Qin S.; ANN-LII CHENG ; Stammberger U.; Locatelli G.; Faivre S. | Hepatology | 181 | 172 | |
13 | 2004 | Recent advances in therapy for gastric cancer | KUN-HUEI YEH ; ANN-LII CHENG | Journal of the Formosan Medical Association | 7 | 7 | |
14 | 2011 | Recent advances in the treatment of metastatic colorectal cancer in Taiwan | Lin Y.-L.; KUN-HUEI YEH ; ANN-LII CHENG | Journal of the Formosan Medical Association | 1 | 1 | |
15 | 2004 | Recent advances in non-surgical treatment for advanced hepatocellular carcinoma | CHIUN HSU ; CHIA-HSIEN CHENG ; ANN-LII CHENG | Journal of the Formosan Medical Association | 23 | 18 | |
16 | 2013 | Randomized Phase III Study of Gemcitabine Plus S-1, S-1 Alone, or Gemcitabine Alone in Patients With Locally Advanced and Metastatic Pancreatic Cancer in Japan and Taiwan: GEST Study | Ueno H.; Ioka T.; Ikeda M.; Ohkawa S.; Yanagimoto H.; Boku N.; Fukutomi A.; Sugimori K.; Baba H.; Yamao K.; Shimamura T.; Sho M.; Kitano M.; ANN-LII CHENG ; Mizumoto K.; Chen J.-S.; Furuse J.; Funakoshi A.; Hatori T.; Yamaguchi T.; Egawa S.; Sato A.; Ohashi Y.; Okusaka T.; Tanaka M.; 鄭安理 | Journal of Clinical Oncology | 508 | 467 | |
17 | 2014 | Radiosensitization by combining an aurora kinase inhibitor with radiotherapy in hepatocellular carcinoma through cell cycle interruption | ZHONG-ZHE LIN ; Chou, Chia-Hung; ANN-LII CHENG ; Liu, Wei-Lin; CHIA-HSIEN CHENG | Int. J. Cancer | 17 | 15 | |
18 | 2021 | Pursuing efficacious systemic therapy for hepatocellular carcinoma | ANN-LII CHENG | Nature reviews Gastroenterology and Hepatology | 9 | 9 | |
19 | 2006 | Primary thyroid lymphoma mimicking subacute thyroiditis [4] | Yang Y.-S.; MU-ZON WU ; ANN-LII CHENG ; TIEN-CHUN CHANG | Acta Cytologica | 9 | ||
20 | 2013 | Primary central nervous system diffuse large B cell lymphoma transformed from orbital mucosa-associated lymphoid tissue lymphoma: Complete response to combined intrathecal and systemic rituximab | HUAI-CHENG HUANG ; ANN-LII CHENG ; CHUNG-WU LIN ; SUNG-HSIN KUO | Annals of Hematology | 5 | 4 | |
21 | 2015 | Predictive biomarkers of sorafenib efficacy in advanced hepatocellular carcinoma: Are we getting there? | YU-YUN SHAO ; CHIH-HUNG HSU ; ANN-LII CHENG | World Journal of Gastroenterology | 36 | 38 | |
22 | 1996 | Polyprenoic acid in hepatocellular carcinoma | CHIH-HSIN YANG ; ANN-LII CHENG | New England Journal of Medicine | 0 | 0 | |
23 | 2016 | Perspectives on the combination of radiotherapy and targeted therapy with DNA repair inhibitors in the treatment of pancreatic cancer | SHIH-HUNG YANG ; TING-CHUN KUO ; Wu H.; JHE-CYUAN GUO ; CHIUN HSU ; CHIH-HUNG HSU ; YU-WEN TIEN ; KUN-HUEI YEH ; ANN-LII CHENG ; SUNG-HSIN KUO | World Journal of Gastroenterology | 23 | 25 | |
24 | 2012 | Parvovirus B19 infection-related acute hepatitis after rituximab-containing regimen for treatment of diffuse large B-cell lymphoma | SHIH-HUNG YANG ; Lin L.-W.; YU-JEN FANG ; ANN-LII CHENG ; SUNG-HSIN KUO | Annals of Hematology | 6 | 2 | |
25 | 2023 | Overall survival with cetuximab every-2-weeks versus standard once-weekly administration schedule for first-line treatment of RAS wild-type metastatic colorectal cancer in patients with left- and right-sided primary tumour location | Kasper, Stefan; Foch, Caroline; Esser, Regina; Lamy, Francois-Xavier; Zhang, Aimar; ANN-LII CHENG ; Rouyer, Magali; Brodowicz, Thomas; Zielinski, Christoph | European journal of cancer (Oxford, England : 1990) | 0 | 1 | |
26 | 2012 | Non-bacterial infections in Asian patients treated with alemtuzumab: a retrospective study of the Asian Lymphoma Study Group | Kim, Seok Jin; Moon, Joon Ho; Kim, Hawk; Kim, Jin Seok; Hwang, Yu Yan; Intragumtornchai, Tanin; Issaragrisil, Surapol; Kwak, Jae Yong; Lee, Je Jung; Won, Jong Ho; Reksodiputro, Arry Harryanto; Lim, Soon Thye; ANN-LII CHENG ; Kim, Won Seog; Kwong, Yok Lam | Leukemia & Lymphoma | 32 | 26 | |
27 | 2013 | No evidence of IGH-MALT1-translocation in the Ma-1 cell line-A reply | SUNG-HSIN KUO ; Weng W.-H.; KUN-HUEI YEH ; Chen L.-T.; ANN-LII CHENG | Genes Chromosomes and Cancer | 1 | 1 | |
28 | 2009 | National Center of Excellence for Clinical Trials and Research at National Taiwan University Hospital | CHIA-CHI LIN ; CHIH-HSIN YANG ; ANN-LII CHENG ; Chan W.-K.; HONG-NERNG HO | Drug Information Journal | 3 | 2 | |
29 | 2020 | A multicenter prospective study of first-line antibiotic therapy for early-stage gastric mucosa-associated lymphoid tissue lymphoma and diffuse large B-cell lymphoma with histological evidence of mucosa-associated lymphoid tissue | Tsai H.-J.; Tai J.J.; Chen L.-T.; MING-SHIANG WU ; KUN-HUEI YEH ; CHUNG-WU LIN ; Wang T.-E.; HSIU-PO WANG ; Yu F.-J.; JYH-MING LIOU ; Hsiao C.-F.; TSU-YAO CHENG ; Yeh H.-J.; Ko C.-W.; Chen M.-J.; Lo G.-H.; Hsu P.-I.; Chang C.-S.; Hwang W.-S.; Chuang S.-S.; Lee H.-W.; CHIA-TUNG SHUN ; Chiu C.-F.; Wang W.-M.; Hsieh C.-Y.; Liu T.-W.; Lin J.-T.; SUNG-HSIN KUO ; ANN-LII CHENG | Haematologica | 5 | 5 | |
30 | 2010 | Molecular targeted therapy for advanced hepatocellular carcinoma: Current status and future perspectives | Ying-Chun Shen ; CHIUN HSU ; ANN-LII CHENG | Journal of Gastroenterology | 61 | 54 | |
31 | 2016 | Modified CLIP with objective liver reserve assessment retains prognosis prediction for patients with advanced hepatocellular carcinoma | YU-YUN SHAO ; TSUNG-HAO LIU ; Lee, Ying-Hui; CHIH-HUNG HSU ; ANN-LII CHENG | J. Gastroenterol. Hepatol. | 26 | 24 | |
32 | 2020 | Milestones in the pathogenesis and management of primary liver cancer | Nault J.-C.; ANN-LII CHENG ; Sangro B.; Llovet J.M. | Journal of Hepatology | 39 | 35 | |
33 | 2012 | Management of colon cancer: Resource-stratified guidelines from the Asian Oncology Summit 2012 | Ku G.; Tan I.B.; Yau T.; Boku N.; Laohavinij S.; ANN-LII CHENG ; Kang Y.-K.; de Lima Lopes G. | The Lancet Oncology | 66 | 61 | |
34 | 2009 | Lamivudine and hepatitis B reactivation | CHIUN HSU ; ANN-LII CHENG ; PEI-JER CHEN | Annals of Internal Medicine | 0 | 0 | |
35 | 2018 | Immunomodulatory Effects of Current Targeted Therapies on Hepatocellular Carcinoma: Implication for the Future of Immunotherapy | Lin Y.-Y.; CHING-TING TAN ; Chen C.-W.; DA-LIANG OU ; ANN-LII CHENG ; CHIUN HSU | Seminars in Liver Disease | 61 | 53 | |
36 | 2020 | IMbrave 050: A Phase III trial of atezolizumab plus bevacizumab in high-risk hepatocellular carcinoma after curative resection or ablation | Hack S.P.; Spahn J.; Chen M.; ANN-LII CHENG ; Kaseb A.; Kudo M.; Lee H.C.; Yopp A.; Chow P.; Qin S. | Future Oncology | 120 | 105 | |
37 | 2019 | Hypofractionated particle beam therapy for hepatocellular carcinoma-a brief review of clinical effectiveness | CHE-YU HSU ; CHUN-WEI WANG ; ANN-LII CHENG ; SUNG-HSIN KUO | World Journal of Gastrointestinal Oncology | 7 | 5 | |
38 | 1997 | High-dose 5-fluorouracil infusional therapy is associated with hyperammonaemia, lactic acidosis and encephalopathy [2] | KUN-HUEI YEH ; ANN-LII CHENG | British Journal of Cancer | 124 | 97 | |
39 | 2013 | Helicobacter pylori and mucosa-associated lymphoid tissue: what's new | SUNG-HSIN KUO ; ANN-LII CHENG | Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program | 45 | 43 | |
40 | 1995 | Growth of E.coli at low temperature dramatically increases the transformation frequency by electroporation | Chuang S.-E.; ANN-LII CHENG ; Chao C.-C. | Nucleic Acids Research | 20 | 19 | |
41 | 2022 | First-line antibiotic treatment in patients with localized extragastric mucosa-associated lymphoid tissue lymphoma | Ming Yao; Shu-Lang Liao; Chung-Wu Lin; Cheng-Ping Wang; WEI-LI MA ; Yi-Hsuan Wei; Jyh-Ming Liou; I-Jong Wang; ANN-LII CHENG ; SUNG-HSIN KUO | eJHaem | 0 | ||
42 | 2021 | Evolution of systemic treatment for advanced hepatocellular carcinoma | Wu T.-C.; YING-CHUN SHEN ; ANN-LII CHENG | Kaohsiung Journal of Medical Sciences | 10 | 9 | |
43 | 2014 | erratum: Oxidative stress enhances AXL-mediated cell migration through AKT1/Rac1-dependent mechanism (Free Radical Biology and Medicine (2013) 65 (1246-1256)) | Huang J.-S.; Cho C.-Y.; Hong C.-C.; Yan M.-D.; Hsieh M.-C.; Lay J.-D.; Lai G.-M.; ANN-LII CHENG ; Chuang S.-E. | Free Radical Biology and Medicine | 0 | 0 | |
44 | 2013 | erratum: Geographic difference in safety and efficacy of systemic chemotherapy for advanced gastric or gastroesophageal carcinoma: A meta-analysis and meta-regression (Gastric Cancer (2012) 15(265-280) DOI 10.1007/s10120-011- 0106-5) | CHIUN HSU ; Ying-Chun Shen ; Cheng C.-C.; ANN-LII CHENG ; Hu F.-C.; KUN-HUEI YEH | Gastric Cancer | 0 | 0 | |
45 | 1998 | Encephalopathy, lactic acidosis, hyperammonaemia and 5-fluorouracil toxicity (multiple letters) [1] | Valik D.; KUN-HUEI YEH ; ANN-LII CHENG | British Journal of Cancer | 3 | 5 | |
46 | 2016 | Dynamic contrast-enhanced MR imaging of advanced hepatocellular carcinoma: Comparison with the liver parenchyma and correlation with the survival of patients receiving systemic therapy | BANG-BIN CHEN ; CHAO-YU HSU ; CHIH-WEI YU ; PO-CHIN LIANG ; CHIUN HSU ; CHIH-HUNG HSU ; ANN-LII CHENG ; TIFFANY TING-FANG SHIH | Radiology | 27 | 25 | |
47 | 2012 | A Critical Evaluation of the Preventive Effect of Antiviral Therapy on the Development of Hepatocellular Carcinoma in Patients with Chronic Hepatitis C or B: A Novel Approach by Using Meta-Regression | YING-CHUN SHEN ; CHIUN HSU ; Cheng C.-C.; Hu F.-C.; ANN-LII CHENG | Oncology | 34 | 29 | |
48 | 2017 | Corrigendum to “Signal transducer and activator of transcription 3 is a major kinase-independent target of sorafenib in hepatocellular carcinoma” (Journal of Hepatology (2017) 66(3) (666–668) (S0168827816307127) (10.1016/j.jhep.2016.12.007)) | Tai W.-T.; ANN-LII CHENG ; Shiau C.-W.; Huang H.-P.; Huang J.-W.; PEI-JER CHEN ; Chen K.-F. | Journal of Hepatology | 0 | 1 | |
49 | 2017 | Corrigendum to “Signal transducer and activator of transcription 3 is a major kinase-independent target of sorafenib in hepatocellular carcinoma” (Journal of Hepatology (2011) 55(5) (1041–1048)(S0168827811001917)(10.1016/j.jhep.2011.01.047)) | Tai W.-T.; ANN-LII CHENG ; Shiau C.-W.; Huang H.-P.; Huang J.-W.; PEI-JER CHEN ; Chen K.-F. | Journal of Hepatology | 1 | 1 | |
50 | 2018 | Corrigendum to “Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: Analysis of two phase III studies” [J hepatol 67 (2017) 999–1008](S0168827817321347)(10.1016/j.jhep.2017.06.026)) | Bruix J.; ANN-LII CHENG ; Meinhardt G.; Nakajima K.; De Sanctis Y.; Llovet J. | Journal of Hepatology | 6 | 4 | |
51 | 2019 | Correction: Urine protein:creatinine ratio vs 24-hour urine protein for proteinuria management: analysis from the phase 3 REFLECT study of lenvatinib vs sorafenib in hepatocellular carcinoma (British Journal of Cancer, (2019), 121, 3, (218-221), 10.1038/s41416-019-0506-6) | Evans T.R.J.; Kudo M.; Finn R.S.; Han K.-H.; ANN-LII CHENG ; Ikeda M.; Kraljevic S.; Ren M.; Dutcus C.E.; Piscaglia F.; Sung M.W. | British Journal of Cancer | 2 | 2 | |
52 | 2022 | Correction to: APASL clinical practice guideline on hepatitis B reactivation related to the use of immunosuppressive therapy | Lau, George; Yu, Ming-Lung; Wong, Grace; Thompson, Alexander; Ghazinian, Hasmik; Hou, Jin-Lin; Piratvisuth, Teerha; Jia, Ji-Dong; Mizokami, Masashi; Cheng, Gregory; Chen, Guo-Feng; Liu, Zhen-Wen; Baatarkhuu, Oidov; ANN-LII CHENG ; Ng, Woon Leung; Lau, Patrick; Mok, Tony; Chang, Jer-Ming; Hamid, Saeed; Dokmeci, A Kadir; Gani, Rino A; Payawal, Diana A; Chow, Pierce; Park, Joong-Won; Strasser, Simone I; Mohamed, Rosmawaiti; Win, Khin Maung; Tanwandee, Tawesak; Sarin, Shiv Kumar; Omata, Masao | Hepatology international | 0 | 0 | |
53 | 2019 | Considerations of heterogeneity in clinical trials for hepatocellular carcinoma | TSUNG-HAO LIU ; YU-YUN SHAO ; LI-CHUN LU ; Ying-Chun Shen ; CHIUN HSU ; ZHONG-ZHE LIN ; CHIH-HUNG HSU ; ANN-LII CHENG | Expert Review of Gastroenterology and Hepatology | 5 | 7 | |
54 | 2007 | Clinical studies with curcumin | CHIH-HUNG HSU ; ANN-LII CHENG | Advances in Experimental Medicine and Biology | 359 | 305 | |
55 | 2010 | Clinical Development and Future Direction for the Treatment of Hepatocellular Carcinoma | Whang-Peng J.; ANN-LII CHENG ; CHIUN HSU ; Chen C.-M. | Journal of Experimental and Clinical Medicine | 25 | 0 | |
56 | 2020 | Challenges of combination therapy with immune checkpoint inhibitors for hepatocellular carcinoma | ANN-LII CHENG ; CHIUN HSU ; Chan S.L.; Choo S.-P.; Kudo M. | Journal of Hepatology | 297 | 267 | |
57 | 2014 | Beware imposters: MA-1, a novel MALT lymphoma cell line, is misidentified and corresponds to Pfeiffer, a diffuse large B-cell lymphoma cell line-A reply: Despite the same 8-code STR, MA-1 and Pfeiffer are cytogenetically diverse | SUNG-HSIN KUO ; Tsai H.-J.; Weng W.-H.; Li C.-C.; KUN-HUEI YEH ; Chen L.-T.; ANN-LII CHENG | Genes Chromosomes and Cancer | 3 | 3 | |
58 | 2013 | The Aurora Kinases Inhibitor VE-465 is a Novel Treatment for Glioblastoma Multiforme | Lee P.-Y.; Chen C.-L.; ZHONG-ZHE LIN ; ANN-LII CHENG ; Chen E.I.-T.; Whang-Peng J.; Huang C.-Y.F. | Oncology | 11 | 9 | |
59 | 2020 | Atezolizumab and Bevacizumab in Hepatocellular Carcinoma. Reply | Finn R.S.; ANN-LII CHENG | The New England journal of medicine | 2 | 8 | |
60 | 2013 | Aspirin antagonizes the cytotoxic effect of methotrexate in lung cancer cells | Yan K.-H.; Lee L.-M.; Hsieh M.-C.; Yan M.-D.; Yao C.-J.; Chang P.-Y.; Chen T.-L.; Chang H.-Y.; ANN-LII CHENG ; Lai G.-M.; Chuang S.-E. | Oncology Reports | 18 | 19 | |
61 | 2017 | Asia–Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update | Omata M.; ANN-LII CHENG ; Kokudo N.; Kudo M.; Lee J.M.; Jia J.; Tateishi R.; Han K.-H.; Chawla Y.K.; Shiina S.; Jafri W.; Payawal D.A.; Ohki T.; Ogasawara S.; PEI-JER CHEN ; Lesmana C.R.A.; Lesmana L.A.; Gani R.A.; Obi S.; Dokmeci A.K.; Sarin S.K. | Hepatology International | 1451 | 1303 | |
62 | 2010 | Asian pacific association for the study of the liver consensus recommendations on hepatocellular carcinoma | Omata M.; Lesmana L.A.; Tateishi R.; PEI-JER CHEN ; Lin S.-M.; Yoshida H.; Kudo M.; Lee J.M.; Choi B.I.; Poon R.T.P.; Shiina S.; ANN-LII CHENG ; Jia J.-D.; Obi S.; Han K.H.; Jafri W.; Chow P.; Lim S.G.; Chawla Y.K.; Budihusodo U.; Gani R.A.; Lesmana C.R.; Putranto T.A.; Liaw Y.F.; Sarin S.K. | Hepatology International | 881 | 860 | |
63 | 2018 | The APPLE association president's message | ANN-LII CHENG | Liver Cancer | 0 | 0 | |
64 | 2019 | The APPLE association president's message | ANN-LII CHENG | Liver Cancer | 0 | 0 | |
65 | 2018 | The APPLE Association President's Message | ANN-LII CHENG | Liver Cancer | 0 | 0 | |
66 | 2018 | The APPLE Association President's Message | ANN-LII CHENG | Liver Cancer | 0 | 0 | |
67 | 2019 | The APPLE association president's message | ANN-LII CHENG | Liver Cancer | 0 | 0 | |
68 | 2017 | The APPLE Association President's Message | ANN-LII CHENG | Liver Cancer | 0 | 0 | |
69 | 2019 | The APPLE Association President's Message | ANN-LII CHENG | Liver Cancer | 0 | 0 | |
70 | 1994 | An alternative method to overcome central venous portable external infusion pump blockage in patients receiving weekly 24-hour high-dose fluorouracil and leucovorin [2] | KUN-HUEI YEH ; ANN-LII CHENG | Journal of Clinical Oncology | 18 | 16 | |
71 | 2014 | Adaptation of international guidelines for metastatic colorectal cancer: An Asian consensus | ANN-LII CHENG ; Li J.; Vaid A.K.; Ma B.B.Y.; Teh C.; Ahn J.B.; Bello M.; Charoentum C.; Chen L.-T.; De Lima Lopes G.; Jr.; Ho G.F.; Kong H.L.; Lam K.O.; Liu T.S.; Park Y.S.; Sriuranpong V.; Sudoyo A.W.; Wang J.-Y.; Zhang J.; Zhang S.Z.; Ciardiello F.; Köhne C.-H.; Shaw M.; Kim T.W. | Clinical Colorectal Cancer | 16 | 15 |